Sino Biopharmaceutical's Earnings Outlook Brighter on Higher Margins -- Market Talk
Dow Jones
Aug 19
0605 GMT - Sino Biopharmaceutical Will likely to see stronger earnings thanks to its higher gross margins, Nomura analysts write in a note. The company's 1H net profit rose 12% to CNY3.4 billion, beating Nomura's estimates, thanks to dividend income of CNY1.5 billion from the Sinovac investment, they say. The company's sales growth in 1H was driven by innovative drug sales of CNY7.8 billion, which accounted for 44% of its continued business revenue, they say. Nomura lifts its 2025 fiscal year's revenue estimates by 0.4%. Nomura raises the stock's target price to HK$9.17 from HK$7.69 and maintains a buy rating. Shares last at HK$7.32. (jiahui.huang@wsj.com; @ivy_jiahuihuang)
(END) Dow Jones Newswires
August 19, 2025 02:05 ET (06:05 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.